Durvalumab Plus Olaparib Administered Prior to Surgery of Resectable Urothelial Bladder Cancer (NEODURVARIB)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Jesús García-Donas, MD PhD
Centro Integral Oncológico Clara Campal
Principal Investigator - Juan F Rodriguez-Moreno, MD
Centro Integral Oncológico Clara Campal
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
10 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Ico Badalona
Badalona, Barcelona, Spain
- Hospital Universitario Central de Asturias
Oviedo, Principality of Asturias, Spain
- Clinica Imq Zorrotzaurre
Bilbao, Spain
- Hospital San Pedro de Alcántara
Cáceres, Spain
- Hospital Universitario Lucus Augusti
Lugo, Spain
- Hopsital Universitario Madrid Sanchinarro (ciocc)
Madrid, Spain
- Hospital Ramón Y Cajal
Madrid, Spain
- Hospital Universitario 12 de Octubre
Madrid, Spain
- Hospital de Navarra
Pamplona, Spain
- Hospital Virgen Macarena
Seville, Spain
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 16 Nov 2018
- Primary completion
- 16 Mar 2020
- Completion
- 16 Mar 2020
- Last update posted
- 6 Apr 2020
- Registered enrollment
- 29
- Registry id
- NCT03534492
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.